Beyond the left ventricle: CMR assessment of right ventricular dysfunction during cancer therapy

Clicks: 1
ID: 323500
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #271 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Cancer therapy can cause left and right ventricular (RV) cancer therapy-related cardiac dysfunction (CTRCD). How patients transition from having normal myocardial function to isolated left ventricular (LV), RV, or biventricular (BV) CTRCD, and the associations of these phenotypes with post-therapy prognostic measures remain unknown. Purpose We aimed to define patterns of ventricular dysfunction during anthracycline and trastuzumab therapy. Methods This ancillary study of the EMBRACE-MRI study included women with early-stage HER2-positive breast cancer treated with sequential anthracycline and trastuzumab, prospectively enrolled between 2014 and 2021 at our Hospitals. LV and RV function were assessed by CMR pre-anthracyclines, post-anthracyclines, at 3 and 6 months during trastuzumab therapy, and early post-completion of trastuzumab. All CMR analyses were performed using CVI42. Cardiopulmonary exercise testing was performed early post-completion of trastuzumab. LV CTRCD was defined based on the CREC criteria while RV CTRCD was defined as a >10% reduction in RVEF from baseline to <49%. Patients were classified as having isolated LV CTRCD, isolated RV CTRCD, or biventricular (BV) CTRCD based on the first CTRCD event. Descriptive statistics were used to summarize baseline clinical characteristics, the timing of CTRCD, and CMR data. Between-group comparisons were evaluated using Wilcoxon rank-sum tests for continuous variables. Results Among the 153 patients (median age 51.4, IQR: [43.5-57.5] years), the first CTRCD event included LV, RV, or BV CTRCD in 36 (24%), 4 (3%) and 6 (4%) patients respectively (Figure 1). The first instance of RV, LV, and BV CTRCD was 3 months, 3 to 6 months, and 12 months after trastuzumab initiation respectively. Patients also transitioned between phenotypes, with one patient with initial RV CTRCD developing BV CTRCD. Baseline demographics characteristics were similar between groups with no difference in cumulative anthracycline dose. However, patients with RV/BV CTRCD had a lower baseline RVEF (58 [55-59] % vs 61 [58-64]%, p=0.02) and more frequently received right-sided radiation (62% vs 35%) (Figure 2). Post-completion of trastuzumab, LV CTRCD patients had lower VO2 max (17.1 vs 19.2 mL/kg/min, p=0.059) and significantly reduced predicted VO2 max (73% vs 89%, p=0.014) compared to RV/BV CTRCD. Conclusion In this cohort of HER2-positive breast cancer patients treated with anthracycline and trastuzumab LV CTRCD was the commonest type of CTRCD, however RV/BV CTRCD occurred in 7% of patients with distinct temporal patterns. LV CTRCD was associated with lower post-treatment functional capacity and RV CTRCD may be more common in those receiving right-sided radiation. These findings underscore the importance of systematic BV monitoring throughout cancer therapy. The long-term prognostic implications of LV vs RV CTRCD is a focus on ongoing investigation.Flow chart, transition between states Baseline characteristics
Reference Key
openalex_W7172276948 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors T Goncalves, S Cai, J Weiss, M Signorile, G Lee, A Koch, E Amir, H Abdel-Qadir, P Thavendiranathan, C Yu
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.195
URL
https://doi.org/10.1093/eurheartjsupp/suag097.195
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.